Mean platelet volume as an indicator of disease activity in systemic lupus erythematosus
Sarkar, R.N.; Bhattacharya, K.; Banerjee, M.
Journal of the Association of Physicians of India 64(1): 68-69
2016
ISSN/ISBN: 0004-5772 PMID: 27727907 Document Number: 689309
Document emailed within 1 workday
Related Documents
Dubois, E.L.; Chandor, S.; Friou, G.J.; Bischel, M. 1971: Progressive systemic sclerosis and localized scleroderma morphea with positive lupus erythematosus cell test and unusual systemic manifestations compatible with systemic lupus erythematosus presentation of 14 cases including 1 set of identical twins 1 with scleroderma and the other with systemic lupus erythematosus review of the literature Medicine (Baltimore) 50(3): 199-222Greco, C.M.; Rudy, T.E.; Manzi, S. 2004: Effects of disease activity, pain, and distress on activity limitations in patients with systemic lupus erythematosus Journal of Rheumatology 31(2): 260-267
Pallis, M.; Hopkinson, N.; Powell, R. 1991: Nailfold capillary density as a possible indicator of pulmonary capillary loss in systemic lupus erythematosus but not in mixed connective tissue disease Journal of Rheumatology 18(10): 1532-1536
Konca, K.; Erken, E.; Ozbek, S. 1996: Do antineutrophil cytoplasmic antibodies correlate with disease activity in systemic lupus erythematosus? Journal of Rheumatology 23(11): 2007-2008
El-Garf, A.; Salah, S.; Shaarawy, M.; Zaki, S.; Anwer, S. 1996: Prolactin hormone in juvenile systemic lupus erythematosus: a possible relationship to disease activity and CNS manifestations Journal of Rheumatology 23(2): 374-377
Leaños-Miranda, A.; Pascoe-Lira, D.; Chávez-Rueda, K.A.; Blanco-Favela, F. 2001: Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity Journal of Rheumatology 28(7): 1546-1553
Pacilio, M.; Migliaresi, S.; Meli, R.; Ambrosone, L.; Bigliardo, B.; Di Carlo, R. 2001: Elevated bioactive prolactin levels in systemic lupus erythematosus--association with disease activity Journal of Rheumatology 28(10): 2216-2221
Blanco-Favela, F.; Quintal-Alvarez, G.; Leaños-Miranda, A. 1999: Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power Journal of Rheumatology 26(1): 55-59
Carr, R.; Forsyth, S.; Sadi, D. 1987: Abnormal responses to ingested substances in murine systemic lupus erythematosus: apparent effect of a casein-free diet on the development of systemic lupus erythematosus in NZB/W mice Journal of Rheumatology. Suppl 14(Suppl 13): 158-165
Neville, C.; Clarke, A.E.; Joseph, L.; Belisle, P.; Ferland, D.; Fortin, P.R. 2000: Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity Journal of Rheumatology 27(3): 675-679
Kiani, A.N.; Magder, L.; Petri, M. 2008: Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity Journal of Rheumatology 35(7): 1300-1306
Tselios, K.; Sarantopoulos, A.; Gkougkourelas, I.; Boura, P. 2014: CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study Clinical and Experimental Rheumatology 32(5): 630-639
Howe, S.E.; Lynch, D.M. 1987: Platelet antibody binding in systemic lupus erythematosus Journal of Rheumatology 14(3): 482-486
Vitali, C.; Bencivelli, W.; Isenberg, D.A.; Smolen, J.S.; Snaith, M.L.; Sciuto, M.; Neri, R.; Bombardieri, S. 1992: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE Clinical and Experimental Rheumatology 10(5): 541-547
Hafez, S.S.; Saad, W.E.S.; Shedid, N.H. 2014: B-cell-attracting chemokine-1 (BCA-1/CXCL13) in systemic lupus erythematosus, its correlation to disease activity and renal involvement Egyptian Journal of Immunology 21(2): 23-32
Lit, L.C.-W.; Wong, C.-K.; Li, E.K.-M.; Tam, L.-S.; Lam, C.W.-K.; Lo, Y.-M.D. 2007: Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus Journal of Rheumatology 34(1): 89-96
Rautenstrauch, H.; Frank, F.; Saal, J.G. 1985: No correlation between suppressor cell function and disease activity in natural history studies of patients with systemic lupus erythematosus Zeitschrift für Rheumatologie 44(3): 133-136
Gheita, T.A.; Abdel Rehim, D.M.; Kenawy, S.A.; Gheita, H.A. 2015: Clinical significance of matrix metalloproteinase-3 in systemic lupus erythematosus patients: a potential biomarker for disease activity and damage Acta Reumatologica Portuguesa 40(2): 145-149
Lolli, C.; Foscoli, M.; Giofrè, R.; Tarquinii, M.; Pasquali, S.; Toschi, G.P. 1993: Cardiac anomalies in systemic lupus erythematosus: their prevalence and relation to duration, disease activity and the presence of antiphospholipid antibodies Giornale Italiano di Cardiologia 23(11): 1125-1134
Sumethkul, K.; Srivitidkul, S. 2017: Prevalence of Chronic Hepatitis B Infection in Patients with Systemic Lupus Erythematosus: Viral Reactivation and Impact on Disease Activity Journal of the Medical Association of Thailand 100(Suppl 1): S124-S130